Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
Saved in:
| Published in: | PLOS ONE |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform
- Primary immune trajectories following a single BNT162b2 vaccination scheme in SARS-CoV-2–naïve individuals
- Notes from the Field: Assessment of Awareness, Use, and Access Barriers to Cooling Centers in Maricopa County, Arizona - August 1-September 15, 2023
- Volume 15, no 1/2023
- Maskay Vol. 15 No. 1
- ID1/ID3 mediate the contribution of skin fibroblasts to local nerve regeneration through Itga6 in wound repair
- Cover & Contents Vol.15 No.1